Is Methenamine Over the Counter for UTIs?

Methenamine is partially available over the counter in the United States, but the OTC version delivers a fraction of the dose used in clinical research. The prescription form, methenamine hippurate, is dosed at 1 gram twice daily for UTI prevention, while the OTC product (sold as Cystex) contains just 162 milligrams per tablet and tops out at roughly 972 milligrams per day even at maximum dosing.¹ That distinction matters more than you might expect, and it shapes nearly every practical question about using methenamine for urinary tract infections.

What the OTC Product Actually Contains

Cystex is the main over-the-counter product marketed for urinary discomfort that contains methenamine. Each tablet combines 162 mg of methenamine with sodium salicylate, a mild pain reliever related to aspirin. The recommended dosing for adults up to age 60 is two tablets three times a day, which delivers a total daily methenamine dose of about 972 mg. That sounds like a reasonable amount until you compare it with prescription methenamine hippurate, which provides 2,000 mg per day, or prescription methenamine mandelate, which delivers 4,000 mg per day.¹

Because Cystex is classified as an OTC product rather than a prescription drug, it is not regulated by the FDA in the same way prescription medications are. This means the manufacturing process does not face the same scrutiny, and there is potential for variability between batches. The product is also marketed primarily for symptom relief during a UTI rather than for long-term prevention of recurrent infections, which is the use case that has actual clinical trial support behind it.

Why the Dose Gap Matters

Methenamine works through a surprisingly old-school chemical reaction: in acidic urine, it breaks down into formaldehyde, which kills bacteria. The catch is that enough formaldehyde has to accumulate in the bladder to reach a concentration that actually does something useful. Lab studies simulating real urinary tract conditions have shown that you need at least 600 to 1,000 micrograms of methenamine per milliliter of urine, combined with a urine pH at or below about 5.85, to generate bactericidal levels of formaldehyde within a couple of hours.² Separate research confirmed that even at a slightly higher pH of 6.0, a methenamine concentration of 750 micrograms per milliliter could produce enough formaldehyde in about three hours to kill bacteria.³

The prescription dose of 1 gram twice daily was designed to maintain those urinary concentrations over a full day. The OTC product’s lower dose raises real questions about whether it can consistently reach those thresholds, and no published clinical trial has tested the Cystex formulation specifically for UTI prevention. So while you can walk into a pharmacy and buy a product containing methenamine without a prescription, you cannot buy the dose or formulation that researchers have actually studied.

What Prescription Methenamine Hippurate Actually Does for Recurrent UTIs

The clinical evidence for methenamine hippurate at prescription doses is genuinely encouraging, particularly for women who get UTIs repeatedly. The largest and most influential recent trial, called ALTAR, compared methenamine hippurate with daily low-dose antibiotics in women with recurrent infections. During a 12-month treatment period, women taking methenamine hippurate had about 1.38 UTI episodes per person-year, compared with 0.89 in the antibiotic group. That absolute difference of roughly half an episode per year fell within the trial’s pre-defined limit for non-inferiority, meaning methenamine hippurate performed well enough to be considered a viable alternative to daily antibiotics.⁴

A more recent trial focused specifically on older women and found a roughly 25% reduction in recurrent UTI frequency compared with placebo, with notably mild side effects.⁵ These are prevention trials, not treatment trials. Methenamine hippurate is not used to clear an active UTI. It is used between episodes to reduce how often they come back. That is an important distinction that gets lost when people see an OTC methenamine product and hope it will treat the infection they have right now.

The Urine pH Problem

Because methenamine depends on acidic urine to generate formaldehyde, anything that raises your urine pH undermines its effectiveness. This is more than a theoretical concern. Potassium citrate, which is itself sometimes used for urinary tract discomfort because it makes urine less acidic and reduces the burning sensation, directly interferes with methenamine’s activation. Research has confirmed that at normal therapeutic doses, potassium citrate alkalinizes urine enough to block the conversion of methenamine to formaldehyde, and the two should not be used together.⁶

You might assume that taking vitamin C (ascorbic acid) alongside methenamine would help by making urine more acidic. That idea has been around for decades, but the evidence is discouraging. A study of elderly patients with indwelling catheters who were taking both methenamine and ascorbic acid found that increasing the vitamin C dose actually raised urine pH rather than lowering it, and the researchers concluded that the value of ascorbic acid for acidifying urine in this setting was questionable.⁷ Diet has a bigger practical impact on urine pH than most supplements. A diet heavy in animal protein tends to produce more acidic urine, while vegetarian and fruit-heavy diets tend to push pH higher.

Bacteria That Dodge It

Methenamine’s reliance on acidic conditions also creates a blind spot against certain types of bacteria. Proteus species, which are a common cause of complicated UTIs especially in people with catheters or structural urinary tract abnormalities, produce an enzyme called urease that breaks down urea into ammonia, driving urine pH upward. Research has confirmed that the use of methenamine against Proteus infections is limited precisely because these bacteria create an alkaline environment that prevents formaldehyde from forming.⁸ If your recurrent UTIs are caused by Proteus or similar urease-producing organisms, methenamine is a poor choice regardless of the dose or formulation.

For the more common UTI culprits, particularly E. coli which causes the majority of uncomplicated infections, this is not usually an issue. E. coli does not significantly alter urine pH, so methenamine can do its job in a normal bladder environment.

Who Benefits Most and Who Should Be Cautious

The strongest evidence supports methenamine hippurate for women with recurrent uncomplicated UTIs, meaning infections that keep coming back but don’t involve kidney problems or structural abnormalities. A study at a large referral center tracked outcomes in 162 women, including both premenopausal and postmenopausal patients, and found success rates of 83% and 77% respectively. Diabetes, immune suppression, and pelvic floor dysfunction did not significantly change those outcomes.⁹ Even among patients using intermittent catheterization, about two-thirds experienced success, though that group was smaller and the evidence is less robust.

A small longitudinal study of postmenopausal women taking methenamine hippurate found not only zero UTIs during the observation period but also improvement in urinary symptoms overall.¹⁰ That is a tiny study and should not be treated as proof of universal benefit, but it does suggest the drug is well tolerated in this population.

People with kidney disease need to be more careful. Methenamine is converted to formaldehyde, and the kidneys handle that clearance. Severe kidney impairment can affect how the drug is processed and increase the risk of irritation. The OTC product, Cystex, contains sodium salicylate, which adds another layer of concern for people with kidney problems, aspirin sensitivity, or those already taking blood thinners.

The Antibiotic Resistance Angle

One of the most compelling reasons clinicians have become interested in methenamine hippurate is that it avoids the antibiotic resistance problem. Every course of antibiotics, whether used to treat or prevent UTIs, exerts selection pressure on bacteria throughout your body, not just in the urinary tract. Over time, this drives the emergence of resistant strains that are harder to treat when a real infection hits. Methenamine hippurate works through formaldehyde generation rather than through the mechanisms that antibiotics target, so it does not promote the same kind of resistance.

This is a big deal for women who have been cycling through repeated courses of nitrofurantoin, trimethoprim, or other prophylactic antibiotics for years. The UK’s National Institute for Health and Care Excellence (NICE) has incorporated methenamine hippurate into its updated guidelines for UTI prevention, explicitly recognizing its potential role in improving antibiotic stewardship.¹¹ The ALTAR trial authors similarly framed methenamine hippurate as appropriate for women with recurrent UTIs, particularly when antibiotic stewardship concerns and patient preferences are factored in.¹²

That said, researchers have begun investigating whether bacteria could develop resistance to formaldehyde itself over time. The concern is early-stage and theoretical at this point, but it is a reminder that no antimicrobial strategy is permanently bulletproof.

Cost Differences Between OTC and Prescription

You might assume the OTC route is cheaper, and on a per-bottle basis it often is. But the economics shift when you look at effectiveness per dollar. The ALTAR trial included a formal cost-effectiveness analysis, and it found that prescription methenamine hippurate was on average slightly less expensive than antibiotic prophylaxis over a year of treatment, while producing comparable health outcomes. When the societal cost of antibiotic resistance was factored in, the economic case for methenamine hippurate grew even stronger.¹³

The OTC product was not included in that analysis, and its lower methenamine content means you may end up spending money on something that does not reach the concentrations shown to be effective in research. If your goal is UTI prevention rather than temporary symptom relief, the prescription version is both the better-studied and potentially more cost-effective option.

Getting a Prescription and What to Expect

Methenamine hippurate requires a prescription in the United States. If you experience recurrent UTIs, defined as two or more confirmed infections in six months or three in a year, you can ask your doctor about it specifically. Many providers are familiar with the drug but have historically defaulted to low-dose antibiotics because that was the standard approach for decades. The ALTAR trial and NICE guideline updates have shifted that conversation, and more clinicians are now open to prescribing methenamine hippurate as a first-line preventive option.

If your doctor does prescribe it, the standard regimen is one gram taken twice daily, usually with food. You will likely be advised to avoid alkalinizing agents and to maintain a diet that does not push your urine pH too high. Some providers will check your urine pH periodically to make sure the drug has the right chemical environment to work. The drug is generally well tolerated. Side effects are mild and mostly gastrointestinal: occasional nausea, stomach upset, or skin rash. Serious adverse events are rare at standard doses.

Why Methenamine Cannot Treat an Active Infection

A common misconception, fueled partly by the OTC product’s marketing as a urinary discomfort remedy, is that methenamine can treat a UTI that is already in progress. It cannot. Formaldehyde generation from methenamine is a slow, steady process designed to keep bacterial counts low in the bladder between infections. It takes hours for meaningful formaldehyde concentrations to build up, and even then the effect is bacteriostatic to mildly bactericidal, not the kind of rapid bacterial killing you need when you already have a full-blown infection with symptoms. Active UTIs require antibiotics prescribed by a healthcare provider, ideally guided by a urine culture to identify the specific bacteria involved and confirm which antibiotics it responds to.

The OTC product muddies this further because its sodium salicylate component provides pain relief that might make you feel like the infection is improving, even though the methenamine content is not clearing the bacteria. Masking symptoms while an infection progresses can lead to complications, especially if the infection ascends to the kidneys.

How Methenamine Hippurate Compares With Other Non-Antibiotic Prevention Strategies

Women searching for ways to prevent recurrent UTIs without antibiotics have several options, and methenamine hippurate sits in an unusual position among them. Cranberry supplements, D-mannose, vaginal estrogen for postmenopausal women, and behavioral modifications like post-intercourse voiding are all commonly discussed. Of these, methenamine hippurate has the strongest clinical trial evidence. It is the only non-antibiotic option that has been tested head-to-head against daily antibiotic prophylaxis in a large randomized trial and demonstrated non-inferiority.

Vaginal estrogen has solid evidence of its own for postmenopausal women, and the two approaches can potentially be combined. The referral center study mentioned earlier found that vaginal estrogen use did not significantly change methenamine hippurate’s success rate, suggesting the two work through different enough pathways that combining them is reasonable.⁹ Cranberry products and D-mannose, while popular, have weaker and more inconsistent evidence behind them. They are unlikely to cause harm, but relying on them as a sole prevention strategy when you are having multiple infections per year is a gamble that the evidence does not strongly support.